Acquisition and Research and Development Funding Collaboration Agreement (Details) - USD ($) $ in Thousands			1 Months Ended	3 Months Ended		9 Months Ended		98 Months Ended
		Jan. 29, 2024	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Jul. 29, 2024	Dec. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development	[1]			$ 98,238	$ 89,737	$ 296,653	$ 316,073
Reduction to research and development expense				2,500		4,800
Deferred research and development funding liability, current				16,269		16,269		$ 16,269		$ 0
Deferred research funding and development liability, less current portion				3,944		3,944		3,944		$ 0
Collaboration And Development Funding Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement, aggregate consideration amount (up to)		$ 75,000
Deferred liability, upfront payment		$ 12,500							$ 12,500
Collaborative Arrangement with F-Star and Acquisition of F-Star Gamma
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development								$ 49,800
Collaborative Arrangement with F-Star and Acquisition of F-Star Gamma | Contingent Payments Upon Achievement of Specialized Clinical Milestone
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent consideration payment triggered			$ 30,000
Contingent consideration recognized				$ 0	$ 0	$ 0

[1] Includes expenses for cost sharing payments due to a related party of $3.4 million and $14.5 million for the three and nine months ended September 30, 2023, respectively.